Neil L. Berinstein
Affiliations: | University of Toronto, Toronto, ON, Canada |
Area:
Immunology, Molecular BiologyGoogle:
"Neil Berinstein"Children
Sign in to add trainee| Laurent K. Verkoczy | grad student | 2000 | University of Toronto |
| Ali A. Zarrin | grad student | 2000 | University of Toronto |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pucilowska J, Egan J, Berinstein N, et al. (2019) Abstract P2-09-12: Perilymphatic IRX-2 cytokine therapy to enhance tumor infiltrating lymphocytes (TILs) and PD-L1 expression preceding curative-intent therapy in early stage breast cancer (ESBC) Cancer Research. 79 |
| Berinstein N, Bence-Buckler I, Laneuville P, et al. (2019) SPIReL: PHASE 2 STUDY DPX-SURVIVAC WITH INTERMITTENT LOW DOSE CYCLOPHOSPHAMIDE AND PEMBROLIZUMAB IN PATIENTS WITH RECURRENT/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA Hematological Oncology. 37: 569-569 |
| Wolf GT, Moyer JS, Kaplan MJ, et al. (2018) IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Oncotargets and Therapy. 11: 3731-3746 |
| Abdul-Wahid A, Cydzik M, Fischer NW, et al. (2018) Serum-derived carcinoembryonic antigen (CEA) activates fibroblasts to induce a local re-modeling of the extracellular matrix that favors the engraftment of CEA-expressing tumor cells. International Journal of Cancer |
| Berinstein NL, McNamara M, Nguyen A, et al. (2018) Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. Oncoimmunology. 7: e1423173 |
| Berinstein NL, Pennell NM, Weerasinghe R, et al. (2018) Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with Y ibritumomab tiuxetan in a phase II study. Hematological Oncology |
| Smyth L, Buckstein R, Pennell N, et al. (2018) Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma. British Journal of Haematology |
| Page DB, Pucilowska J, Berinstein NL, et al. (2018) Tumor infiltrating lymphocyte recruitment in patients with early stage breast cancer after intramammary IRX-2 cytokine immunotherapy. Journal of Clinical Oncology. 36: 7-7 |
| Smyth L, Buckstein R, Nancy P, et al. (2017) Prolonged Molecular and Clinical Remissions in Follicular Lymphoma Patients Treated with HDT/ASCT and Combination Immunotherapy with Rituximab and Interferon α Blood. 130: 4069-4069 |
| Berinstein N, Smyth L, Pennell N, et al. (2017) PROLONGED MOLECULAR AND CLINICAL REMISSIONS IN FOLLICULAR LYMPHOMA PATIENTS TREATED WITH HDT/ASCT AND COMBINATION IMMUNOTHERAPY WITH RITUXIMAB AND INTERFERON α Hematological Oncology. 35: 365-366 |